{"filing":{"accession_number":"0001193125-26-341239","cik":"0001974640","ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"apge-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/apge-20260810.htm"},"events":[{"id":26359,"run_id":23950,"accession_number":"0001193125-26-341239","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Item 2.02 disclosure centers on Apogee's second quarter 2026 financial results, including cash position ($1.3 billion), R\u0026D expenses ($67.3 million), G\u0026A expenses ($24.3 million), and net loss ($85.9 million), furnished as a press release exhibit. While the press release also announces the pending AbbVie acquisition ($135.11/share, ~$10.9 billion equity value), the Item 2.02 classification specifically addresses financial results. The acquisition is material but constitutes a separate M\u0026A event; however, since Item 2.02 is explicitly designated for \"Results of Operations and Financial Condition,\" the earnings_release classification is most appropriate for this Item, though the filing also contains ma_activity elements.","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27451,"accession_number":"0001193125-26-341239","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 2.02 disclosure centers on Apogee's second quarter 2026 financial results, including cash position ($1.3 billion), R\u0026D expenses ($67.3 million), G\u0026A expenses ($24.3 million), and net loss ($85.9 million), furnished as a press release exhibit. While the press release also announces the pending AbbVie acquisition ($135.11/share, ~$10.9 billion equity value), the Item 2.02 classification specifically addresses financial results. The acquisition is material but constitutes a separate M\u0026A event; however, since Item 2.02 is explicitly designated for \"Results of Operations and Financial Condition,\" the earnings_release classification is most appropriate for this Item, though the filing also contains ma_activity elements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:21:38.870252+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27451,"accession_number":"0001193125-26-341239","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 2.02 disclosure centers on Apogee's second quarter 2026 financial results, including cash position ($1.3 billion), R\u0026D expenses ($67.3 million), G\u0026A expenses ($24.3 million), and net loss ($85.9 million), furnished as a press release exhibit. While the press release also announces the pending AbbVie acquisition ($135.11/share, ~$10.9 billion equity value), the Item 2.02 classification specifically addresses financial results. The acquisition is material but constitutes a separate M\u0026A event; however, since Item 2.02 is explicitly designated for \"Results of Operations and Financial Condition,\" the earnings_release classification is most appropriate for this Item, though the filing also contains ma_activity elements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:21:38.870252+00:00","company_name":"Apogee Therapeutics, Inc.","ticker":"APGE","filing_date":"2026-08-10"}]}